Charles River Laboratories to Release Q4 2024 Earnings and 2025 Guidance

Charles River Laboratories International, Inc. (NYSE: CRL) has announced that it will release its fourth-quarter and full-year 2024 financial results along with 2025 guidance on Wednesday, February 19th, before market opening. The company has scheduled a conference call at 8:30 a.m. ET on the same day to discuss these results.

Investors can access a live webcast of the conference call through the Investor Relations section of the company's website at ir.criver.com. A replay will be accessible through the same website.

Charles River Laboratories specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies, and academic institutions. Net sales break down by activity as follows: discovery and safety assessment services (63.4%), development and sale of research models and related services (19.2%), and development of solutions used in drug manufacturing processes (17.5%). Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%), and other (0.4%).



Charles River Laboratories' financial performance over the past year can be analyzed by looking at key metrics such as revenue, earnings, and margins. According to the provided data, the company's revenue for the last 12 months was $4.06 billion, with a gross profit of $1.45 billion and an operating income of $598.02 million. The net income for the same period was $413.08 million, resulting in earnings per share (EPS) of $8.00.

Looking at the trends, the company's revenue growth rate was -0.016% over the past year, indicating a slight decline in revenue. However, it is essential to consider that this decline might be due to various factors, such as market conditions or strategic decisions made by the company.

In the upcoming earnings report, analysts expect Charles River Laboratories to report a profit of $2.52 per share on a diluted basis, up 2.4% from $2.46 per share in the year-ago quarter. This suggests that the company's earnings may be stabilizing or even improving compared to the previous year.

Additionally, the company's forward P/E ratio is 15.82, which is lower than its trailing P/E ratio of 20.43. This indicates that the market may be pricing in some level of uncertainty or potential growth opportunities for the company in the future.



In summary, while Charles River Laboratories' revenue growth has been relatively flat over the past year, the company's earnings are expected to improve in the upcoming earnings report. The forward P/E ratio suggests that the market may be anticipating potential growth opportunities for the company in the future. Investors should closely monitor the company's earnings release and conference call to gain insights into its financial performance and strategic direction.